UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 64

Sortiert nach

Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials

European journal of cancer (1990), 2014-07, Vol.50 (11), p.1916-1924

2014

Volltextzugriff (PDF)

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29

European journal of cancer (1990), 2014-03, Vol.50 (4), p.706-712

2014

Volltextzugriff (PDF)

A systematic review and meta‐analysis of utility estimates in melanoma

British journal of dermatology (1951), 2018-02, Vol.178 (2), p.384-393

2018

Volltextzugriff (PDF)

Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: A systematic review of contemporary randomized trials

Lung cancer (Amsterdam, Netherlands), 2012-09, Vol.77 (3), p.537-544

2012

Volltextzugriff (PDF)

More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials

Breast (Edinburgh), 2017-02, Vol.31, p.99-104

2017

Volltextzugriff (PDF)

Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life

Gynecologic oncology, 2013-07, Vol.130 (1), p.162-168

2013

Volltextzugriff (PDF)

Timing of Androgen Deprivation Therapy for Prostate Cancer Patients after Radiation: Planned Combined Analysis of Two Randomized Phase 3 Trials

International journal of radiation oncology, biology, physics, 2018-11, Vol.102 (3), p.S148-S148

2018

Volltextzugriff (PDF)

Patients' Perceptions of Health-related Quality of Life During and After Adjuvant Radiotherapy for T1N0M0 Breast Cancer

Clinical oncology (Royal College of Radiologists (Great Britain)), 2015-01, Vol.27 (1), p.9-15

2015

Volltextzugriff (PDF)

EP11.03-29 Immunotherapy and Overall Survival in Advanced NSCLC: A Systematic Review of Randomised Trials

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S632-S633

2023

Volltextzugriff (PDF)

P0201 Circulating biomarkers and outcomes in a phase 2 trial of first-line everolimus alternating with sunitinib for advanced renal cell carcinoma (ANZUP 0901—the EVERSUN Trial)

European journal of cancer (1990), 2014-05, Vol.50, p.e65-e65

2014

Volltextzugriff (PDF)

P0211 EVERSUN: A phase 2 trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (ANZUP Trial 0901)

European journal of cancer (1990), 2014-05, Vol.50, p.e68-e69

2014

Volltextzugriff (PDF)

Historical cross-trial comparisons for competing treatments in advanced breast cancer – An empirical analysis of bias

European journal of cancer (1990), 2010-02, Vol.46 (3), p.541-548

2010

Volltextzugriff (PDF)

Preferences for cancer treatments: an overview of methods and applications in oncology

Annals of oncology, 2012-05, Vol.23 (5), p.1104-1110

2012

Volltextzugriff (PDF)

602P Using scenarios to explain survival times – attitudes of women with gynaecological cancer

Annals of oncology, 2022-09, Vol.33, p.S821

2022

Volltextzugriff (PDF)

LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)

Annals of oncology, 2023-10, Vol.34, p.S1325-S1325

2023

Volltextzugriff (PDF)

1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)

Annals of oncology, 2023-10, Vol.34, p.S1014-S1014

2023

Volltextzugriff (PDF)

1831P Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?

Annals of oncology, 2023-10, Vol.34, p.S991-S991

2023

Volltextzugriff (PDF)

1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)

Annals of oncology, 2023-10, Vol.34, p.S968-S969

2023

Volltextzugriff (PDF)

What do oncologists think patients with incurable cancer should be told about their prognosis?

Annals of oncology, 2018-11, Vol.29, p.ix136-ix136

2018

Volltextzugriff (PDF)

564O_PR Oncologists’ preferences for recommending expensive anticancer drugs

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

564O_PR Oncologists' preferences for recommending expensive anticancer drugs

Annals of oncology, 2016-12, Vol.27, p.ix184-ix184

2016

Volltextzugriff (PDF)

Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy

Annals of oncology, 2017-08, Vol.28 (8), p.1849-1855

2017

Volltextzugriff (PDF)

A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD)

International journal of radiation oncology, biology, physics, 2021-11, Vol.111 (3), p.S10-S11

2021

Volltextzugriff (PDF)

DREAM3R: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma: A Phase 3 Randomised Trial

International journal of radiation oncology, biology, physics, 2022-02, Vol.112 (2), p.e9-e10

2022

Volltextzugriff (PDF)

Patients’ preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?

Annals of oncology, 2018-02, Vol.29 (2), p.370-376

2018

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(62)

Publikationsform

Artikel
(64)

Sprache

Englisch
(64)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(20)
Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Oncology
(19)
Female
(15)
Adult
(14)
Middle Aged
(14)
Aged
(11)
Male
(11)
Hematology, Oncology And Palliative Medicine
(9)
Prognosis
(9)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Treatment Outcome
(7)
Tumors
(7)
Pharmacology. Drug Treatments
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Chemotherapy
(5)
Quality Of Life
(5)
Survival Analysis
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29

A systematic review and meta‐analysis of utility estimates in melanoma

Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: A systematic review of contemporary randomized trials

More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials

Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life

Timing of Androgen Deprivation Therapy for Prostate Cancer Patients after Radiation: Planned Combined Analysis of Two Randomized Phase 3 Trials

Patients' Perceptions of Health-related Quality of Life During and After Adjuvant Radiotherapy for T1N0M0 Breast Cancer

EP11.03-29 Immunotherapy and Overall Survival in Advanced NSCLC: A Systematic Review of Randomised Trials

P0201 Circulating biomarkers and outcomes in a phase 2 trial of first-line everolimus alternating with sunitinib for advanced renal cell carcinoma (ANZUP 0901—the EVERSUN Trial)

P0211 EVERSUN: A phase 2 trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (ANZUP Trial 0901)

Historical cross-trial comparisons for competing treatments in advanced breast cancer – An empirical analysis of bias

Preferences for cancer treatments: an overview of methods and applications in oncology

602P Using scenarios to explain survival times – attitudes of women with gynaecological cancer

LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)

1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)

1831P Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?

1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)

What do oncologists think patients with incurable cancer should be told about their prognosis?

564O_PR Oncologists’ preferences for recommending expensive anticancer drugs

564O_PR Oncologists' preferences for recommending expensive anticancer drugs

Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy

A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD)

DREAM3R: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma: A Phase 3 Randomised Trial

Patients’ preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?

Suchergebnisse filtern